Meeting
2020 ASCO Virtual Scientific Program
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101.
Authors
Tracy Batchelor
Brigham and Women's Hospital, Boston, MA
Tracy Batchelor , Sharmila Giri , Amy S. Ruppert , Nancy L. Bartlett , Eric D. Hsi , Bruce D. Cheson , Lakshmi Nayak , John Paul Leonard , James L. Rubenstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT01511562
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8042)
DOI
10.1200/JCO.2020.38.15_suppl.8042
Abstract #
8042
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Role of high-dose chemotherapy with autologous stem cell transplantation for primary central nervous system lymphoma: A systematic review.
First Author: Shaha Nabeel
Poster
2013 ASCO Annual Meeting
Multicenter randomized phase II trial of methotrexate (MTX) and temozolomide (TMZ) versus MTX, procarbazine, vincristine, and cytarabine for primary CNS lymphoma (PCNSL) in the elderly: An Anocef and Goelams Intergroup study.
First Author: Antonio Marcilio Padula Omuro
Poster
2013 ASCO Annual Meeting
Preirradiation chemotherapy with methotrexate, rituximab, and temozolomide and post-irradiation temozolomide for primary central nervous system lymphoma: RTOG 0227 phase II study results.
First Author: Jon Glass
Poster
2012 ASCO Annual Meeting
CNS-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT) for CNS relapse of aggressive lymphomas: Final analysis of a phase II study.
First Author: Agnieszka Korfel